New findings have ruled out any meaningful mortality benefit for Covid-19 patients of lopinavir-ritonavir, a combination of antiviral drugs used in HIV treatment. Scientists from the University of Oxford studied the potential of the drug combination for coronavirus in the large-scale ongoing RECOVERY trial, in which several drugs are being tested in a randomised manner. Over 11,800 patients have been enrolled in the UK for the trial. Of which, 1,596 patients were randomised to lopinavir-ritonavir and compared with 3,376 patients randomised to usual care alone. No significant difference in mortality for lopinavir-ritonavir was observed in comparison to usual care.